Effects of exendin-4 on the intrarenal renin-angiotensin system and interstitial fibrosis in unilateral ureteral obstruction mice: Exendin-4 and unilateral ureteral obstruction

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 17, Issue 4, 2016, Pages 1-10

  Le, Ying ^a   Zheng, Zongji ^a   Xue, Junyu ^a   Cheng, Mengling ^a   Guan, Meiping ^a   Xue, Yaoming ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin II; Angiotensin converting enzyme; Angiotensin converting enzyme 2; Exendin 4; Intrarenal reninangiotensin system; TGF 1 Smad3; Unilateral ureteral obstruction

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN 5; ANGIOTENSIN 6; ANGIOTENSIN 7; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; COLLAGEN TYPE 1; DIPEPTIDYL CARBOXYPEPTIDASE; EXENDIN 4; FIBRONECTIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ACE PROTEIN, HUMAN; ACTA2 PROTEIN, MOUSE; ACTIN; ANGIOTENSIN I (1-7); MESSENGER RNA; PEPTIDE; PEPTIDE FRAGMENT; VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; KIDNEY TUBULE DAMAGE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RADIOIMMUNOASSAY; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNILATERAL URETER OBSTRUCTION; URETER OBSTRUCTION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; FIBROSIS; GENETICS; KIDNEY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; URETERAL OBSTRUCTION;

ACTINS; ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; COLLAGEN TYPE I; FIBRONECTINS; FIBROSIS; KIDNEY; MALE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; PEPTIDES; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM; RNA, MESSENGER; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; URETERAL OBSTRUCTION; VENOMS;

EID: 85017435757     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320316677918     Document Type: Article

References (30)

1. Saran R, Li Y, Robinson B, et al. US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis 2015; 66(1 Suppl 1): S1-S305.
2. McCullough K, Sharma P, Ali T, et al. Measuring the population burden of chronic kidney disease: A systematic literature review of the estimated prevalence of impaired kidney function. Nephrol Dial Transplant 2012; 27: 1812-1821.
3. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 2011; 7: 684-696.
4. Duffield JS. Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest 2014; 124: 2299-2306.
5. Ruggenenti P, Cravedi P and Remuzzi G. Mechanisms and treatment of CKD. J Am Soc Nephrol 2012; 23: 1917-1928.
6. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-E9.
7. Hamming I, Cooper ME, Haagmans BL, et al. The emerging role of ACE2 in physiology and disease. J Pathol 2007; 212: 1-11.
8. Kobori H, Nangaku M, Navar LG, et al. The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007; 59: 251-287.
9. Rüster C and Wolf G. Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis. J Am Soc Nephrol 2011; 22: 1189-1199.
10. Ye M, Wysocki J, William J, et al. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: Implications for albuminuria in diabetes. J Am Soc Nephrol 2006; 17: 3067-3075.
11. Bernardi S, Toffoli B, Zennaro C, et al. High-salt diet increases glomerular ACE/ACE2 ratio leading to oxidative stress and kidney damage. Nephrol Dial Transplant 2012; 27: 1793-1800.
12. Mizuiri S, Hemmi H, Arita M, et al. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis 2008; 51: 613-623.
13. Eng J, Kleinman WA, Singh L, et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267: 7402-7405.
14. Park CW, Kim HW, Ko SH, et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 2007; 18: 1227-1238.
15. Kodera R, Shikata K, Kataoka HU, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its antiinflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011; 54: 965-978.
16. Mima A, Hiraoka-Yamomoto J, Li Q, et al. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCbeta activation in diabetes. Diabetes 2012; 61: 2967-2979.
17. Ojima A, Ishibashi Y, Matsui T, et al. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression. Am J Pathol 2013; 182: 132-141.
18. Xu WW, Guan MP, Zheng ZJ, et al. Exendin-4 alleviates high glucose-induced rat mesangial cell dysfunction through the AMPK pathway. Cell Physiol Biochem 2014; 33: 423-432.
19. Zeng Y, Li C, Guan M, et al. The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms. Cardiovasc Diabetol 2014; 13: 32.
20. Nagle RB, Bulger RE, Cutler RE, et al. Unilateral obstructive nephropathy in the rabbit. I. Early morphologic, physiologic, and histochemical changes. Lab Invest 1973; 28: 456-467.
21. Chevalier RL, Forbes MS and Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 2009; 75: 1145-1152.
22. Weigert C, Brodbeck K, Klopfer K, et al. Angiotensin II induces human TGF-beta 1 promoter activation: Similarity to hyperglycaemia. Diabetologia 2002; 45: 890-898.
23. Sato M, Muragaki Y, Saika S, et al. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003; 112: 1486-1494.
24. Li J, Qu X, Yao J, et al. Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes 2010; 59: 2612-2624.
25. Skov J, Dejgaard A, Frøkiær J, et al. Glucagon-like peptide-1 (GLP-1): Effect on kidney hemodynamics and reninangiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab 2013; 98: E664-E671.
26. Hirata K, Kume S, Araki S, et al. Exendin-4 has an antihypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun 2009; 380: 44-49.
27. Kim M, Platt MJ, Shibasaki T, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 2013; 19: 567-575.
28. Ishibashi Y, Matsui T, Ojima A, et al. Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A. Microvasc Res 2012; 84: 395-398.
29. Zimmerman DL, Zimpelmann J, Xiao F, et al. The effect of angiotensin-(1-7) in mouse unilateral ureteral obstruction. Am J Pathol 2015; 185: 729-740.
30. Zhang K, Meng X, Li D, et al. Angiotensin(1-7) attenuates the progression of streptozotocin-induced diabetic renal injury better than angiotensin receptor blockade. Kidney Int 2015; 87: 359-369.